Inhibition of peptic ulcer relapse by ranitidine and ecabet independently of eradication of Helicobacter pylori: A prospective, controlled study versus ranitidine

Hepato-Gastroenterology

Volumn 50, Issue 50, 2003, Pages 577-581

  Koizumi, Wasaburo ^a   Tanabe, Satoshi ^a   Imaizumi, Hiroshi ^a   Kida, Mitsuhiro ^a   Ohida, Masahito ^a   Koshida, Yoko ^a   Mitomi, Hiroyuki ^a   Hosaka, Yoshio ^a   Nagaba, Shizuka ^a   Sasaki, Tohru ^a   Higuchi, Katsuhiko ^a   Saigenji, Katsunori ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ecabet; Helicobacter pylori; Peptic ulcer; Relapse

Indexed keywords

12 SULFODEHYDROABIETIC ACID; RANITIDINE;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; HELICOBACTER PYLORI; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; STOMACH ULCER; TREATMENT OUTCOME;

ANTI-ULCER AGENTS; DITERPENES; DITERPENES, ABIETANE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PROSPECTIVE STUDIES; RANITIDINE; RECURRENCE;

EID: 0037350773     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease: Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272:65-69.
2. The European Helicobacter pylori Study Group: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41:8-13.
3. Soll AH: Medical treatment of peptic ulcer disease: practice guidelines. JAMA 1996; 275:622-629.
4. Japanese Association of Helicobacter Research: Helicobacter Research 2000; 4:444-454.
5. Lam SJ, et al: Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13:1-12.
6. Versalovic J, et al: Mutations in 23 S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40:477-480.
7. Goodwill A, et al: Metronidazole resistance in Helicobacter pylori is due to null mutation in a gene (rdx A) that encodes an oxygen-insensitive NADPH nitroductase. Mol Microbiol 1998; 28:383-393.
8. de Boer WA, et al: How to treat Helicobacter pylori infection-should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. Eur J Gastroenterol Hepatol 1996; 8:709-716.
9. Megraud F: Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997; 11(Suppl 1):43-53.
10. AA van Zwet, et al: Stable amoxicillin resistance in Helicobacter pylori. Lancet 1998; 352:1595.
11. Labenz J, et al: Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112:1442-1447.
12. Ito Y, et al: Metabolic fate of a new anti-ulcer drug(+)-(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl7-(1- methyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). II. Distribution in the rat stomach. J Pharmacobiodyn 1991; 14:547-554.
13. Kinoshita M, et al: Relationship between gastroprotective effect of locally acting antiulcer agent ecabet and its binding to gastric mucosa in rats. Comparison with sucralfate. Dig Dis Sci 1995; 40:661-667.
14. Kinoshita M, et al: Ecabet, a novel locally-acting anti-ulcer agent, protects the integrity of the gastric mucosal gel layer from pepsin-induced disruption in the rat. Aliment Pharmacol Ther 1999; 13:687-694.
15. Ito Y, et al: Effects of the new anti-ulcer drug ecabet (TA-2711) on pepsin activity. I. Inactivation of enzyme protein. Jpn J Pharmacol 1993; 62:169-174.
16. Ito Y, et al: Ecabet, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. Eur J Pharmacol 1998; 345:193-198.
17. Shibata K, et al: Bactericidal activity of a new antiulcer agent, ecabet, against Helicobacter pylori under acidic conditions. Antimicrob Agents Chemother 1995; 39:1295-1299.
18. Shibata K, et al: The inhibitory effect of ecabet on ATPase of Helicobacter pylori. Gut 1998; 43(Suppl 2):A12.
19. Hayashi S, et al: Effect of ecabet on Helicobacter pylori adhesion to gastric epithelial cells. J Gastroenterol 1997; 32:593-597.
20. Price AB: The Sydney system: histological division. J Gastroenterol Hepatol 1991; 6:209-222.
21. Grossman MI, et al: Peptic ulcer: new therapies, new diseases. Ann Int Med 1981; 95:609-627.
22. Saigenji K, et al: Risk factors for duodenal ulcer relapse: three-year follow-up during famotidine maintenance therapy. Dig Endosc 1995; 7:226-233.
23. Takemoto T, et al: Ranitidine and sucralfate as maintenance therapy for gastric ulcer disease: endoscopic control and assessment of scarring. Gut 1989; 30:1692-1697.
24. Asaka M, et al: Causal role of Helicobacter pylori in peptic ulcer relapse. J Gastroenterol 1994; 29(Suppl VII):134-138.